MBRX News and Press, Moleculin Biotech Inc. From 10/05/20

Moleculin Appoints Elizabeth Cermak to Board of Directors PR Newswire HOUSTON, Oct. 5. 2020 HOUSTON , Oct. 5 . 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a ...

Moleculin Biotech ([[MBRX]] +3.4%) announced interim first cohort data from the Emory University physician-sponsored Phase 1 trial, with WP1066 (AflacST1901) for the treatment of childhood brain tumors.First three patients received WP1066 dose level of 4 mg/kg wi...

Palm Beach, FL – October 1, 2020 – The global market for brain tumor therapeutics is projected to see significant growth over the next several years. A brain tumor is an abnormal growth of tissue in the brain or central spine that can disrupt proper brain function. Although th...

Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University WP1066 demonstrates activity in DIPG, rare form of pediatric brain tumor PR Newswire HOUSTON, Oct. 1, 2020 HOUSTON , Oct. 1, 2020 ...

Moleculin Biotech ([[MBRX]] +2.3%) says that its research team has discovered a molecule WP1096 within its portfolio of antimetabolites that exhibit vitro antiviral activity against SARS-CoV.The independent laboratory testing of the antiviral activity of its ...

Moleculin Biotech ([[MBRX]] +3.8%) has discovered a new molecule, named as WP1096, within its antimetabolites portfolio, that has showed significant in vitro antiviral activity against SARS-CoV-2.Though, the company says it is in progress with its lead antiviral candidate WP1122, an...

Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New Antimetabolites Increases antiviral drug candidates to three PR Newswire HOUSTON, Sept. 29, 2020 HOUSTON , Sept. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc....

Moleculin Biotech  (NASDAQ: MBRX ) has contracted with an independent laboratory to test the antiviral activity of its WP1122 portfolio in a COVID-19 animal model. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ...

HOUSTON , Sept. 14, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has contracted with an ...

HOUSTON , Sept. 10, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will...